Kancera AB | Balance Sheet

Fiscal year is January-December. All values SEK Thousands.
2013
2014
2015
2016
2017
Cash & Short Term Investments
14,118.00
22,974.00
15,567.00
57,759.00
27,775.00
Total Accounts Receivable
971.00
467.00
2,214.00
860.00
3,099.00
Inventories
-
2,706.00
-
-
-
Other Current Assets
269.00
405.00
485.00
6,385.00
1,719.00
Total Current Assets
15,358.00
26,552.00
18,266.00
65,004.00
32,593.00
Net Property, Plant & Equipment
4,291.00
3,868.00
3,145.00
2,028.00
632.00
Intangible Assets
6,000.00
6,000.00
6,000.00
6,000.00
18,000.00
Total Assets
25,649.00
36,420.00
27,411.00
73,032.00
51,225.00
Accounts Payable
3,068.00
1,102.00
1,254.00
2,125.00
3,423.00
Other Current Liabilities
2,125.00
6,529.00
2,732.00
8,520.00
6,145.00
Total Current Liabilities
5,193.00
7,631.00
3,986.00
10,645.00
9,568.00
Long-Term Debt
1,500.00
1,500.00
-
-
-
Other Liabilities
-
-
1,500.00
2,862.00
2,946.00
Total Liabilities
6,693.00
9,131.00
5,486.00
13,507.00
12,514.00
Common Equity (Total)
18,956.00
27,289.00
21,925.00
59,525.00
38,711.00
Total Shareholders' Equity
18,956.00
27,289.00
21,925.00
59,525.00
38,711.00
Total Equity
18,956.00
27,289.00
21,925.00
59,525.00
38,711.00
Liabilities & Shareholders' Equity
25,649.00
36,420.00
27,411.00
73,032.00
51,225.00

About Kancera AB

View Profile
Address
Karolinska Institutet Science Park
Solna AB 171 48
Sweden
Employees -
Website http://www.kancera.com
Updated 09/14/2018
Kancera AB engages in the research, development, and sale of drug candidate to pharmaceutical companies. Its portfolio includes Fractalkine, ROR inhibitors, HDAC6, and PFKFB3 projects. The company was founded by Hakan Mellstedt on April 28, 2010 and is headquartered in Solna, Sweden.